Pacer Advisors Inc. Has $1.49 Million Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Pacer Advisors Inc. lessened its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 2.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 5,049 shares of the biotechnology company’s stock after selling 145 shares during the quarter. Pacer Advisors Inc.’s holdings in Axon Enterprise were worth $1,486,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AXON. Blue Trust Inc. increased its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the period. ICA Group Wealth Management LLC bought a new stake in shares of Axon Enterprise during the 4th quarter valued at about $26,000. Trivant Custom Portfolio Group LLC acquired a new stake in Axon Enterprise during the first quarter worth approximately $31,000. First PREMIER Bank bought a new stake in Axon Enterprise in the first quarter worth approximately $33,000. Finally, Rise Advisors LLC boosted its holdings in shares of Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after buying an additional 47 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 0.5 %

AXON opened at $393.25 on Friday. Axon Enterprise, Inc. has a fifty-two week low of $190.01 and a fifty-two week high of $398.74. The firm has a market capitalization of $29.68 billion, a P/E ratio of 114.99, a PEG ratio of 10.56 and a beta of 0.94. The company’s 50-day moving average is $354.54 and its 200 day moving average is $319.42. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company’s revenue was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.80 EPS. Research analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

AXON has been the topic of several research analyst reports. Jefferies Financial Group began coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Barclays increased their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities boosted their target price on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC reissued a “buy” rating and issued a $400.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 7th. Finally, Northland Securities upped their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $365.38.

Insiders Place Their Bets

In other news, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the sale, the president now directly owns 228,166 shares of the company’s stock, valued at approximately $82,103,253.44. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at $1,121,052,771.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, President Joshua Isner sold 25,811 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the transaction, the president now directly owns 228,166 shares of the company’s stock, valued at $82,103,253.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 317,981 shares of company stock valued at $115,662,734. Insiders own 6.10% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.